Stock Events

Elanco Animal Health 

$12.64
31
-$0.23-1.83% Today

Statistics

Day High
12.92
Day Low
12.63
52W High
18.8
52W Low
8.52
Volume
1,784,088
Avg. Volume
7,031,848
Mkt Cap
6.24B
P/E Ratio
-4.79
Dividend Yield
-
Dividend
-

Earnings

8MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
0.05
0.18
0.32
0.45
Expected EPS
0.27
Actual EPS
0.34

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ELAN. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Zoetis
ZTS
Mkt Cap81.7B
Zoetis is a global leader in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines, directly competing with Elanco in both the companion and livestock animal product markets.
Merck &
MRK
Mkt Cap323.59B
Merck & Co., through its animal health division, offers veterinary pharmaceuticals, vaccines, and health management solutions and services, making it a direct competitor to Elanco in multiple segments of the animal health industry.
Phibro Animal Health
PAHC
Mkt Cap355.5M
Phibro Animal Health Corporation operates in the animal health and mineral nutrition markets, offering medicated feed additives, which puts it in direct competition with Elanco's product offerings.
Idexx Laboratories
IDXX
Mkt Cap40.69B
IDEXX Laboratories, Inc. provides diagnostic, detection, and information systems for veterinary, livestock, and poultry services, competing with Elanco in the animal health diagnostics market.
Abbott Laboratories
ABT
Mkt Cap181.3B
Abbott Laboratories, through its animal health division (before divestiture), offered products that competed with Elanco in diagnostics and nutrition, although its focus has shifted, it remains a competitor through legacy products and technologies.
Pfizer
PFE
Mkt Cap163.88B
Pfizer, prior to the spin-off of its animal health division into Zoetis, was a direct competitor in the development and commercialization of animal health products, and it maintains a presence in the market through ongoing investments and partnerships.
Elia SA/NV
ELI.BR
Mkt Cap6.76B
Elia System Operator provides infrastructure and services for the energy sector but is included erroneously as it does not compete in the animal health sector, illustrating the importance of accurate industry classification.

Analyst Ratings

17$Average Price Target
The highest estimate is $21.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
50%
Hold
25%
Sell
25%

About

Process Industries
Agricultural Commodities/Milling
Manufacturing
Pharmaceutical Preparation Manufacturing
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
Show more...
CEO
Jeff Simmons
Employees
9300
Country
US
ISIN
US28414H1032
WKN
000A2N6BH

Listings